



## Pyxis Oncology to Participate in September Investor and Industry Conferences

August 21, 2025

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences.

### Investor Conferences

- **2025 Cantor Global Healthcare Conference**, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one-on-one meetings.
- **H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference**, New York, NY, Monday, September 8, 10:30 a.m. ET – Fireside chat and investor one-on-one meetings.

### Industry Conference

- **2<sup>nd</sup> Annual ADC and Novel Conjugates Partnering and Investment Summit**, Boston, MA, Tuesday, September 9, 3:20 p.m. ET – Company presentation (not webcast).

Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website, [ir.pyxisoncology.com](https://ir.pyxisoncology.com).

### About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.

To learn more, visit [www.pyxisoncology.com](https://www.pyxisoncology.com) or follow us on [Twitter](#) and [LinkedIn](#).

### Pyxis Oncology Contact

Jitu Wadhane  
Principal Financial and Accounting Officer  
[IR@pyxisoncology.com](mailto:IR@pyxisoncology.com)

### Media

Molly Devlin  
Real Chemistry  
[mdevlin@realchemistry.com](mailto:mdevlin@realchemistry.com)